If approved, the fund will become the first private credit infrastructure fund to be listed on HKEX. The fund invests in assets across renewables, power, utilities, data centres, telecommunications, transport, healthcare and accommodation.
The HK$155 a share offer is a 33% premium over Hang Seng's 30-day average closing price; HSBC already owns 63% of the HKEX-listed bank. Hang Seng's after tax profits declined 30% in H1 2025. HSBC has paused buybacks.
Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.
The Hong Kong Stock Exchange has eased IPO public float requirements and has made reforms in the IPO price discovery process; it is also carrying out a further consultation; meanwhile, listings continue apace.
The ETF, launched with BOCHK Asset Management, will track the iBoxx Tadawul Government & Agencies Sukuk Index; global sukuk issuance neared $200bn in 2024.
A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.